Patents by Inventor Kirsten EICKHOFF

Kirsten EICKHOFF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Opthalmic compositions comprising F6H8
    Patent number: 11896559
    Abstract: The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: February 13, 2024
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Frank Löscher, Hartmut Voss, Sonja Krösser, Kirsten Eickhoff, Daniela Willen, Markus Beier, Thomas Schlüter
  • OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES
    Publication number: 20230398065
    Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 ?g.
    Type: Application
    Filed: June 12, 2023
    Publication date: December 14, 2023
    Inventors: Bernhard GÜNTHER, Frank LÖSCHER, Kirsten EICKHOFF
  • Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
    Patent number: 11723861
    Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 ?g.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 15, 2023
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Frank Löscher, Kirsten Eickhoff
  • Pharmaceutical compositions comprising nebivolol
    Patent number: 11576893
    Abstract: The present invention relates to pharmaceutical compositions comprising the selective beta 1 (B1)-receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 14, 2023
    Assignee: NOVALIQ GMBH
    Inventors: Frank Löscher, Kirsten Eickhoff, Diana Strehl
  • OPHTHALMIC COMPOSITIONS COMPRISING TAFLUPROST FOR THE TREATMENT OF GLAUCOMA
    Publication number: 20210228595
    Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein the composition comprises tafluprost and a semifluorinated alkane.
    Type: Application
    Filed: April 24, 2019
    Publication date: July 29, 2021
    Inventors: Frank LÖSCHER, Diana STREHL, Kirsten EICKHOFF
  • PHARMACEUTICAL COMPOSITIONS COMPRISING TIMOLOL
    Publication number: 20210121471
    Abstract: The present invention relates to pharmaceutical composition comprising the beta 1(?1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.
    Type: Application
    Filed: March 25, 2019
    Publication date: April 29, 2021
    Inventors: Frank LÖSCHER, Sonja KRÖSSER, Diana STREHL, Bernhard HAUPTMEIER, Kirsten EICKHOFF
  • PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL
    Publication number: 20210106558
    Abstract: The present invention relates to pharmaceutical compositions comprising the selective beta 1 (B1)-receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 15, 2021
    Inventors: Frank LÖSCHER, Kirsten EICKHOFF, Diana STREHL
  • OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES
    Publication number: 20200268648
    Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 ?g.
    Type: Application
    Filed: September 25, 2018
    Publication date: August 27, 2020
    Inventors: Bernhard GÜNTHER, Frank LÖSCHER, Kirsten EICKHOFF
  • OPTHALMIC COMPOSITIONS COMPRISING F6H8
    Publication number: 20200268682
    Abstract: The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.
    Type: Application
    Filed: October 3, 2018
    Publication date: August 27, 2020
    Inventors: Bernhard GÜNTHER, Frank LÖSCHER, Hartmut VOSS, Sonja KRÖSSER, Kirsten EICKHOFF, Daniela WILLEN, Markus BEIER, Thomas SCHLÜTER